Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak associated with Artificial Tears

Marissa K Grossman,Danielle A Rankin,Meghan Maloney,Richard A Stanton,Paige Gable,Valerie A Stevens,Thomas Ewing,Katharine Saunders,Sarah Kogut,Elizabeth Nazarian,Sandeep Bhaurla,Jehan Mephors,Joshua Mongillo,Susan Stonehocker,Jeanette Prignano,Nickolas Valencia,Argentina Charles,Kiara McNamara,William A Fritsch,Shannon Ruelle,Carrie Ann Plucinski,Lynn Sosa,Belinda Ostrowsky,D Cal Ham,Maroya S Walters,Audrey Brezak,Allison C Brown,Nicole Burton,Rebekah Carman,Dawn Chinn-Flournoy,Jennifer Connolly,Jennifer L Dale,Carole Dieterly,Ashlie Dowdell,Jennifer Driscoll,Jalysa Erskine,Monica Giacomucci,Lajune Harris,Cam-Van Huynh,Melissa Judson,Manisha Juthani,Eric N Keller,Lori Koenecke,Alison Laufer Halpin,Stephen LaVoie,Victoria LeGarde,Jennifer MacFarquhar,Arif Mahmud,Michael Mamerow,Elise Mantell,Greta Michaelson,Jason Mitchell,Tisha Mitsunaga,Marika Mohr,Jennifer L Morgan,Heather Moulton-Meissner,Judith Noble-Wang,Kelly Oakeson,Juliana Reyes,Alessandro Rossi,Emily Schneider,Adrienne Sherman,Gloria Shin,Marla M Sievers,Megan Sredl,Ann-Catherine Stanton,Sheila van Twuyver,Homero Aguilar,Amir Alavi,Rocio Balbuena,Jasna Braut-Taormina,Hollianne Bruce,Wiley Chambers,Kai-Shun Chen,Kristen Clancy,Michelle Cockrell,Karlos Crayton,Michael Cyrus,Marisa D'Angeli,Maria Diaz,Jan Dollete,Samuel Eskenazi,Lorene Fong,Rosalie Giardina,Jennifer Gogley,William Greendyke,Susan Hadman,Hollis Houston,Catherine Huck,Philip Istafanos,Amber Jean-Louis,Deborah Jones,Molly Kratz,Thao Kwan,Sammie La,Susan Lance,Megan Lasure,Cynthia Longo,Maria Machado,Gillian McAllister,Sherri McGarry,Susannah McKay,Derek L Miller,Marissa Musk,Kelsey O'Yong,Elvis Patel,Arthur Pightling,Allison Rodriguez,Jeffery Rogers,Haydee Romero,Mona Satyam,Matthew Silverman,Gail Skolek,Amanda J Smith,Anna Stahl,Luis Torres,Kavita K Trivedi,Nadine Wilmott,for the Multistate Pseudomonas Outbreak Investigation Group

DOI: https://doi.org/10.1093/cid/ciae052

IF: 20.999

2024-02-06

Clinical Infectious Diseases

Abstract:Background Carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa (CP-CRPA) are extensively drug resistant bacteria. We investigated the source of a multistate CP-CRPA outbreak. Methods Cases were defined as a U.S. patient's first isolation of P. aeruginosa sequence type 1203 with the carbapenemase gene blaVIM-80 and cephalosporinase gene blaGES-9 from any specimen source collected and reported to CDC between January 1, 2022–May 15, 2023. We conducted a 1:1 matched case-control study at the post-acute care facility with the most cases, assessed exposures associated with case status for all case-patients, and tested products for bacterial contamination. Results We identified 81 case-patients from 18 states, 27 of whom were identified through surveillance cultures. Four (7%) of 54 case-patients with clinical cultures died within 30 days of culture collection, and four (22%) of 18 with eye infections underwent enucleation. In the case-control study, case-patients had increased odds of receiving artificial tears compared to controls (crude matched OR: 5.0, 95% CI: 1.1, 22.8). Overall, artificial tears use was reported by 61 (87%) of 70 case-patients with information; 43 (77%) of 56 case-patients with brand information reported use of Brand A, an imported, preservative-free, over-the-counter (OTC) product. Bacteria isolated from opened and unopened bottles of Brand A were genetically related to patient isolates. FDA inspection of the manufacturing plant identified likely sources of contamination. Conclusions A manufactured medical product serving as the vehicle for carbapenemase-producing organisms is unprecedented in the U.S. The clinical impacts from this outbreak underscore the need for improved requirements for U.S. OTC product importers.

immunology,infectious diseases,microbiology